RecruitingNCT07662096
A First-In-Human Study of ARO-033 in Adult Participants
PHASE1 · 84 planned enrolment
- Countries listed
- 1
- Registry update
- September 15, 2026
immortal.lifePublic trial registrations naming Arrowhead Pharmaceuticals as an industry lead sponsor.
This is an independent registry-name view, not a verified corporate profile, portfolio valuation, ownership map, endorsement, or investment recommendation.
This does not mean that no transaction exists. A record appears only after its disclosure source and the connection to this exact registry sponsor identity are separately verified.
PHASE1 · 84 planned enrolment